Form 4 for ABCL AbCellera Biologics Inc.
Accepted 2021-11-22 00:00:00 ET · period of report 2021-11-18 · accession 0001209191-21-066133 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-11-22 | 2021-11-18 | ABCL | Hansen Carl L. G. | CEO, Dir, 10% | M - OptEx | $15.03 | +224.5K | 224.5K | New | +$3.37M |
| D | 2021-11-22 | 2021-11-18 | ABCL | Hansen Carl L. G. | CEO, Dir, 10% | M - OptEx | $0.00 | -224.5K | 4.99M | -4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2021-11-18 | M | A | 224,500 | $15.03 | 224,500 | D | — | — | |
| 2 | Derivative | Share option (right to buy) | 2021-11-18 | M | D | 224,500 | $0.00 | 4,992,810 | D | $2.70 · — to 2030-11-18 | 224,500 Common Shares | (F3) The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date |